Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403557 | 0.91 | KDM4E (0.41) | — | |
| SCHEMBL3561887 | 0.86 | KDM4E (0.56) | PIK3CD | |
| SCHEMBL3635795 | 0.85 | CYP2A6 (0.55) | — | |
| SCHEMBL3565759 | 0.84 | PIK3CD (0.44) | PIK3CDMAP4K4 | |
| SCHEMBL2402279 | 0.83 | — | — | |
| SCHEMBL3562069 | 0.82 | KDM4E (0.47) | MAP4K4 | |
| SCHEMBL3560170 | 0.81 | MAP4K4 (0.46) | MAP4K4 | |
| SCHEMBL3563217 | 0.81 | ABL1 (0.44) | — | |
| SCHEMBL2405941 | 0.81 | PTGS1 (0.47) | — | |
| SCHEMBL2405333 | 0.80 | HSD17B1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | claimed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | claimed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | claimed |
| US-8415380-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2011-10-27 | — | — | US | disclosed |
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | disclosed |
| EP-2142527-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | PIK3CD 2350/4885MAP4K4 2389/4885 |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | PIK3CD 2350/4885MAP4K4 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.